MedDataX Logo

Electronic Study for Anastrozole Pharmacovigilance Evaluation

NCT ID: NCT00558168

Last Updated: 2008-07-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1850 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-01-31

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Collecting information regarding adverse events from patients on treatment with anastrazole with early stage breast cancer

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Patient's Anastrozole Compliance to Therapy Programme

NCT00555867

Breast Cancer
TERMINATED

Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer

NCT00078832

Breast Cancer
COMPLETED PHASE3

Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer

NCT00357110

Breast Cancer
COMPLETED PHASE2

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

NCT00256698

Breast Cancer
COMPLETED PHASE3

Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer

NCT00588003

Breast Cancer
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Early Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Post-menopausal Early Invasive Breast Cancer Patients who are under anastrazole treatment, who have normal renal and hepatic functions.

Exclusion Criteria

* Metastatic breast cancer patients, previous hormonal therapy, other malignancies.
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nejdet Uskent

Role: PRINCIPAL_INVESTIGATOR

Kadir Has University Medical School

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ARI-IPEP-0104

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer
NCT00544986 COMPLETED PHASE4
Secondary Adjuvant Long Term Study With Arimidex
NCT00295620 COMPLETED PHASE3
Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer
NCT00562458 COMPLETED
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer
NCT00871858 COMPLETED PHASE2
Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
NCT00259090 COMPLETED PHASE2
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
NCT01300351 COMPLETED PHASE3
3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer
NCT00300508 COMPLETED PHASE3
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
NCT01953588 ACTIVE_NOT_RECRUITING PHASE3
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
NCT00287534 COMPLETED PHASE2
Study of Breast Cancer Prevention by Letrozole in High Risk Women
NCT00579826 COMPLETED PHASE2
Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole
NCT00543127 TERMINATED PHASE3
Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer
NCT00629616 COMPLETED PHASE2
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
NCT00530868 COMPLETED PHASE2
Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer
NCT01077453 COMPLETED PHASE1
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
NCT02007512 COMPLETED PHASE2
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
NCT00005886 COMPLETED PHASE1
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
NCT00248170 COMPLETED PHASE3
Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
NCT00638391 COMPLETED
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density
NCT00238316 COMPLETED PHASE2
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621 ACTIVE_NOT_RECRUITING PHASE3
A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
NCT01602380 ACTIVE_NOT_RECRUITING PHASE3
Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy
NCT00542594 TERMINATED
Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
NCT00332852 COMPLETED PHASE3
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
NCT00921115 COMPLETED PHASE2
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
NCT01151215 TERMINATED PHASE2